MedTrace Logo

A Study to Determine the Pharmacokinetic Profile of BMS-986165 Tablets

NCT04065932 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2021-01-06

No results posted yet for this study

Summary

A Study to Determine the Drug Level Profile of Different formulations of BMS-986165 Tablets

Conditions

Interventions

DRUG

BMS-986165-01

Participants will receive BMS- 986165 -01 in prototype formulation

DRUG

BMS-986165 Tablet

Participants will receive BMS-986165 in tablet form.

DRUG

Famotidine

Participants will receive a previously dosed BMS-985165-01 Prototype Tablet at the same dose level following administration of famotidine

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-08-22
Primary Completion
2019-12-08
Completion
2019-12-10

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04065932 on ClinicalTrials.gov